AAIC 2026 LiBBY THC-CBD Agitation Trial: What the Findings Mean for Rural Dementia Families

Purified THC-CBD oil cut severe agitation in hospice dementia, hinting at home-based relief for rural families.

At AAIC 2026, the Phase 2 LiBBY trial reported that twice-daily purified THC-CBD oil lowered agitation — restlessness, aggression and distress — in 120 hospice-eligible people with Alzheimer's or other dementia. For rural dementia families, the findings point to a possible future hospice-based treatment that does not depend on frequent travel to a specialist center.

LiBBY stands for Life's End Benefits of cannaBidiol and tetrahYdrocannabinol. It focused on late-stage dementia at the end of life. The results were first reported in London on July 14.

Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.

Table of Contents

What did the trial test?

Researchers randomized hospice-eligible adults with dementia and agitation to THC-CBD oil or placebo. According to Pennington Biomedical Research Center, participants took a purified twice-daily oil of 2 mg THC plus 100 mg CBD, with a half dose in week 1 and full dose in weeks 2-12. Treatment lasted 12 weeks across multiple U.S.

sites. The trial centered on hospice-eligible late-stage dementia. That group is often left out of drug trials. The National Institute on Aging funded the work through the Alzheimer's Clinical Trials Consortium.

How much did agitation improve?

Agitation was measured with the Cohen-Mansfield Agitation Inventory. It scores how often behaviors like pacing, calling out and aggression occur. The THC-CBD group had a 6.27-point greater drop than placebo at the 2-week primary endpoint.

The gap grew to an 8.23-point greater drop through week 12. Clinicians also rated overall change. As described in the Alzheimer's Association's AAIC 2026 trial summary, 83.9% improved on THC-CBD versus 30.5% on placebo at week 2. By week 12, 87.2% versus 23.6% improved, or nearly 9 in 10 treated patients.

How safe was the study oil?

Overall adverse events were close between groups. They occurred in 46.7% on treatment and 42.4% on placebo. Serious events were higher with treatment, at 23.3% versus 11.9%.

Investigators judged zero serious events related to the study drug. Context matters here because these were Phase 2 topline results in only 120 end-of-life patients. As reported by The Irish Times, the data were not yet peer-reviewed or published and tested an investigational study-only oil, not store or dispensary cannabis.

Why does this matter outside cities?

Rural families often get less end-of-life support. According to Dartmouth Health describing a JAMA study, only 44.8% of decedents in the most rural ZIP codes received hospice versus 52.4% in urban areas, with rural hospice analysis showing less intensive symptom help. Long drives and few specialists make agitation crises harder to manage.

LiBBY used a practical design for that problem. It avoided requiring travel to trial sites for assessments, which reduced dropout, as reported by Being Patient. If larger trials confirm benefit, a hospice-delivered oil could fit home-based care. It would not require repeated memory-clinic visits.

What can rural families do now?

This oil is not available by prescription. Families should not substitute dispensary edibles, smoked cannabis or over-the-counter CBD.

Dose, purity and THC content differ sharply from the study oil. Bring the log to every care meeting. Small pattern changes often guide safer next steps.

  • Ask the hospice or palliative nurse for a written agitation plan
  • Keep a short log of triggers, time of day, pain, hunger and sleep
  • Review all sedating drugs and alcohol use at each visit
  • Ask whether any agitation trial allows remote visits or home assessments

You Might Also Like

HelpDementia.com

Dementia, Alzheimer's, Caregiving & Healthy Aging Guidance

© 2026 HelpDementia.com. All rights reserved.

Educational information only. It is not medical advice and does not replace care from a qualified clinician.